ImmVirX presents on its Phase 1a Clinical Study at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Strong recruitment – commenced April 2023, 8 patients to date. Strong clinician interest across multiple sites.  Intralesional administration well tolerated, no dose-limiting toxicities.  Early signs of induction of potentially beneficial inflammatory cytokines/chemokines, such as CXCL10. Phase 1b combination with checkpoint inhibitor to open in early 2024. Melbourne, Australia 6 November 2023 – ImmVirX Pty Limited, a life […]

ImmVirX raising $25m led by renowned healthcare VC OneVentures

One Ventures

– Up to A$25 million to be raised in Series B Financing, funding ImmVirX through to 2026 – Leading healthcare venture capital investor OneVentures subscribing for A$15 million – Up to $10 million to be raised from existing shareholders and placement of any shortfall – Dr Jeannie Joughin, a Principal at OneVentures, to join ImmVirX […]

ImmVirX enters the clinic with next generation oncolytic virus

First patient on trial in colorectal, gastric and ovarian cancer study (CP-IVX001) Melbourne, Australia 11 April 2023 – ImmVirX Pty Limited, a clinical stage oncology company focused on developing next-generation, receptor targeted oncolytic viral immunotherapies to transform outcomes for patients with some of the most prevalent and challenging cancer types, today announced that the first patient […]

ImmVirX receives $2.81M R&D tax refund for FY22

R and D

ImmVirX receives $2.81M R&D tax refund for FY22 Melbourne, Australia 28 November 2022 – ImmVirX Pty Limited, a life sciences company focused on developing next-generation, receptor targeted oncolytic viral immunotherapies to transform outcomes for patients with some of the most prevalent and challenging cancer types, has received a $2,813,837 Research and Development (R&D) tax refund […]

ImmVirX reports on operations for FY22

Immvirx review

Melbourne, Australia 26 September 2022 – ImmVirX Pty Limited, a life sciences company focused on developing next-generation, receptor targeted oncolytic viral immunotherapies to transform outcomes for patients with some of the most prevalent and challenging cancer types, is pleased to report on its operations for the year ending 30 June 2022. The year has seen […]

ImmVirX receives $858,183 R&D tax refund

R and D

Melbourne, Australia 4 March 2022 – ImmVirX Pty Limited, a life sciences company focused on developing next-generation, receptor targeted oncolytic viral immunotherapies to transform outcomes for patients with some of the most prevalent and challenging cancer types, today announced that it has received a $858,183 Research and Development (R&D) tax refund as part of the […]

ImmVirX extends Research Services Agreement with University of Newcastle & HMRI through to 2024

Immvirx

Melbourne, Australia 6 December 2021 – ImmVirX Pty Limited, a life sciences company focused on developing next-generation, receptor targeted oncolytic viral immunotherapies to transform outcomes for patients with some of the most prevalent and challenging cancer types, today announced the option to extend its relationship with the University of Newcastle through to December 2024.     Under the ongoing Research Services […]

ImmVirX closes upsized $25m Series A financing

Immvirx

Melbourne, Australia 8 November 2021 – ImmVirX Pty Limited, a life sciences company focused on developing next-generation, receptor targeted oncolytic viral immunotherapies to transform outcomes for patients with some of the most prevalent and challenging cancer types, today announced the successful upsizing and completion of its $25m Series A financing.   The initial tranche of $22m […]